Experimental cell therapy targets Hard-to-Treat nerve diseases
Disease control
Recruiting now
This early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC